Andreas Scheel
Director/Board Member at Pancella Therapeutics, Inc.
Profile
Andreas Scheel has held positions as a Director at panCELLa, Inc. and as a Member-Supervisory Board at Pancella Therapeutics, Inc.
Andreas Scheel active positions
| Companies | Position | Start |
|---|---|---|
Pancella Therapeutics, Inc.
 Pancella Therapeutics, Inc. BiotechnologyHealth Technology Pancella Therapeutics, Inc. develops novel therapies for geno dermatoses. The company is headquartered in Toronto, Canada. | Director/Board Member | - |
panCELLa, Inc.
 panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Pancella Therapeutics, Inc.
Pancella Therapeutics, Inc. BiotechnologyHealth Technology Pancella Therapeutics, Inc. develops novel therapies for geno dermatoses. The company is headquartered in Toronto, Canada. | Health Technology |
panCELLa, Inc.
panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Commercial Services |
- Stock Market
- Insiders
- Andreas Scheel
